Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
The START Center for Cancer Research Takes a Major Step Forward in its Mission to Bring the Hope of Cancer Research to Communities Globally
On Friday, the Japanese company inked a deal with Cancer Research UK to bring one of its cancer drug candidates into the clinic. According to Sosei, the agreement will have Cancer Research UK run a Phase I/IIa trial of Sosei’s cancer candidate HTL00397322, an EP4 antagonist. The candidate will be evaluated as both a combination therapy and a monotherapy. While no exact financial details were given, Sosei will still hold the program’s license after the study reads out.
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical trial of VAC2, an allogeneic cancer vaccine product candidate, for the treatment of non-small cell lung cancer (“NSCLC”). Under the terms of an existing agreement, Cancer Research UK will complete the ongoing clinical trial and Lineage has now assumed responsibility for further clinical development of the VAC2 product candidate and any future development opportunities derived from the VAC platform.
Cancer Research UK have announced that the first patient has been dosed in a clinical trial testing a new immunotherapeutic in patients with the most common type of lung cancer.
HOUSTON and SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world's leading cancer charity, today announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies (NCT05057013).
Cancer Research UK reports ‘most successful financial year’ for its spinouts
ASCO and Friends of Cancer Research call on vaccine makers and trial sponsors to include more cancer patients in trials of COVID-19 vaccines.
Melanoma skin cancer deaths have shot up in the UK rising two and half times since the 1970s, according to figures released by Cancer Research UK.